Cancer – AALL1731: A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Condition or Therapy:
B-Acute Lymphoblastic Leukemia
Category:
Cancer and Blood Disorders
Study Number: AALL1731
What is the goal of this study?
The overall goal of Part I of this study is to collect information about leukemia and patient response to the first phase of treatment, called Induction. The rest of therapy is called post-Induction (Part II). The goal of post-Induction therapy is to get rid of any remaining leukemia cells and keep the leukemia from coming back. Researchers also want to understand if children with localized B-LLy receiving “standard risk” B-ALL therapy maintain good treatment outcomes.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are B-ALL patients without DS, between 1 and 9 years old
- Are B-ALL patients with DS, between 1 and 30 years old
- Are B-LLy patients with or without DS, between 1 and 30 years old
- Are B-ALL patients without DS with an initial white blood cell count of greater than 50,000/μL
- B-ALL patients with DS are eligible regardless of the presenting WBC
- Individuals with newly diagnosed B-cell ALL, with or without Down syndrome:
- Greater than 25% blasts on a BM aspirate;
- OR if a BM aspirate is not obtained or is not diagnostic of B-ALL, the diagnosis can be established by a pathologic diagnosis of B-ALL on a BM biopsy;
- OR a complete blood count (CBC) documenting the presence of at least 1,000/μL circulating leukemic cells;
- OR individual has newly diagnosed B-cell LLy Murphy Stages I or II (see Appendix VII for staging), with or without Down syndrome.
- Greater than 25% blasts on a BM aspirate;
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.
Study Location(s):
Seattle Children's Main Hospital Campus
Principal Investigator:
Dr. Kasey Leger
Research Center: Center for Clinical and Translational Research